Study of SPG302 in Adults With Schizophrenia

Running, not enrolling · Phase 2 · Has a placebo group

Conditions studied: Schizophrenia

In brief

This Phase 2 study described herein will evaluate the safety, efficacy, tolerability, and pharmacodynamics of SPG302 in adults with a primary diagnosis of schizophrenia.

Key facts

Study ID

NCT06442462

Run by

Spinogenix

People needed

32

Starts

2024-08-01

Expected to finish

2026-03-01

Last updated by the study team

2026-02-06

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 18-65
• Primary diagnosis of schizophrenia
• Clinical laboratory values within normal range or < 1.5 times ULN
• Currently prescribed only one antipsychotic medication, with stable dose for at least 4 weeks
• Able and willing to provide written informed consent

You may not qualify if…

• Any physical or psychological condition that prohibits study completion
• Known cardiac disease
• Active or history of malignancy in the past 5 years
• History of clinically significant CNS event or diagnosis in the past 5 years.
• Receipt of investigational products within 30 days
• Blood donation within 30 days

Where it is running

• CenExel CNS — Garden Grove, California, United States
• Box Hill Hospital - Eastern Health — Box Hill, Victoria, Australia
• Multidisciplinary Alfred Psychiatry Research Centre (MAPrc) — Melbourne, Victoria, Australia

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.